"The FDA Can Declare War on Alzheimer's," by George Vradenburg and Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation. Read the full article here.
Each quarter, we will share a few key pieces from a variety of publications highlighting interesting advancements in Alzheimer’s, neuroscience and research more broadly. Read the full newsletter here.
To date, there are 57 Phase 2 and 23 Phase 3 ongoing clinical trials to test potential Alzheimer’s medications. Read the full article here
By 2029, more than 20 percent of people in the United States will be over the age of 65. That’s why the race to find effective treatments for Alzheimer’s disease feels urgent. Read the full article here.
Dr. David Morgan and George Vradenburg penned an op-ed in The Hill about the need for the healthcare system to prepare for innovative Alzheimer's treatments.
George Vradenburg appeared on NPR's The Diane Rehm Show to discuss the cost of Alzheimer's care and its impact on families. Read the full transcript.
According to a recent analysis by ResearchersAgainstAlzheimer's, 17 drugs are on pace to launch in the next five years.
Read the Press Release
"Alzheimer's research gets a boost," by Dr. David Morgan, CEO of the University of South Florida's Health Byrd Alzheimer's Institute.
Last month, George Vradenburg and ResearchersAgainstAlzheimer’s held an expert webinar exploring what is needed to find a cure for this cruel disease.
"Inside Report from Washington and G7/8: Focus on Resources, Clinical Trials, and Regulatory Change"